Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

C&C Group launches EUR 15m share buyback

(Sharecast News) - C&C Group announced the launch of a €15m share buyback programme on Thursday, beginning on the same day, as part of its broader plan to return up to €150m to shareholders over the financial years ending February 2025, 2026 and 2027. The FTSE 250 drinks company said the initiative reflected the board's confidence in the company's medium-term outlook and strong cash generation.

It said the programme marked the third tranche of C&C's capital return strategy, following two previous buybacks totalling €30m.

Shares repurchased under the current initiative would be cancelled, thus reducing the company's share capital.

The buyback would be executed by broker J&E Davy, acting independently under pre-set parameters.

C&C said the programme would run until 1 September, subject to market conditions.

It would be conducted under the authority granted at the August 2024 annual general meeting, allowing the repurchase of up to 10% of issued share capital, and in compliance with UK and EU market abuse and securities regulations.

C&C, which manufactures and distributes a portfolio of branded alcoholic and non-alcoholic beverages across the UK and Ireland, said the buyback represented the most effective use of capital in the current environment.

At 1119 BST, shares in C&C Group were up 4.8% at 144.2p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.